Related Experiment Video
Updated: Apr 30, 2026

Isolation, Characterization, and Purification of Macrophages from Tissues Affected by Obesity-related Inflammation
Published on: April 3, 2017
Hypercortisolism in obesity-associated hypertension
Amy G Varughese1, Oksana Nimkevych, Gabriel I Uwaifo
1Section of Endocrinology, Diabetes and Metabolism, Department of Medicine, Louisiana State University Health Sciences Center (LSUHSC), 1542 Tulane Avenue, New Orleans, LA, 70112, USA, avarug@lsuhsc.edu.
Insights
Obesity-related hypertension, particularly when linked to hypercortisolism, requires specific management. Treatments targeting the renin-angiotensin-aldosterone system and cortisol activity show promise for this distinct hypertension subtype.
Area of Science:
- Endocrinology
- Cardiology
- Metabolic Disorders
Background:
- Obesity is a global health issue linked to increased cardiovascular disease risk.
- Hypertension is the most common comorbidity in obesity, significantly raising cardiovascular risk.
- Hypercortisolism, including various Cushing's syndromes, is increasingly recognized as a key factor in obesity-induced hypertension.
Purpose of the Study:
- To provide a comprehensive review of glucocorticoid-mediated obesity hypertension.
- To explore the epidemiology, etiopathogenesis, and management strategies for this condition.
Main Methods:
- Literature review synthesizing current data on hypercortisolism and hypertension in obesity.
- Analysis of diagnostic considerations and therapeutic options.
Main Results:
- Hypercortisolism is an important consideration in managing obesity hypertension resistant to standard treatments.
- Antihypertensives targeting the renin-angiotensin-aldosterone system demonstrate efficacy in hypercortisolism-mediated obesity hypertension.
- Interventions aimed at reducing cortisol production or blocking its action are beneficial.
Conclusions:
- Glucocorticoid excess plays a significant role in a subtype of obesity hypertension.
- Effective management involves addressing hypercortisolism alongside conventional hypertension therapies.
- Further research into specific therapeutic strategies for hypercortisolism-mediated obesity hypertension is warranted.
Abstract:
Obesity is prevalent worldwide and associated with co-morbidities that result in increased cardiovascular risk. Hypertension is the most prevalent obesity comorbidity associated with increased cardiovascular risk. Obesity hypertension is a distinct subtype of essential hypertension. While endogenous Cushing's syndrome is an uncommon cause of both obesity and hypertension, the recent recognition of other hypercortisolemic states has raised the profile of hypercortisolism as an important contributor in obesity hypertension. The high prevalence of exogenous, iatrogenic, pseudo, and subclinical Cushing's syndromes makes hypercortisolism an important diagnostic consideration in the evaluation and management of patients with obesity hypertension who are resistant to conventional management. Available data suggest that the renin-angiotensin-aldosterone system modulating antihypertensives have the best efficacy in hypercortisolism-mediated obesity hypertension. Strategies aimed at reducing cortisol production and action also have utility. This review provides a comprehensive overview of the epidemiology, etiopathogenesis and management options available for glucocorticoid-mediated obesity hypertension.
More Related Videos
Related Concept Videos
Cushing Syndrome II: Pathophysiology
Cushing Syndrome I: Introduction
Obesity
Hypothalamic-Pituitary Axis
Hypertension II: Pathophysiology
Adrenal Gland Disorders
Adrenal insufficiency, characterized by insufficient cortisol and aldosterone production, leads to conditions like Addison's disease. This disorder, affecting the adrenal cortex, exhibits symptoms such as skin bronzing, dehydration, low blood pressure, fatigue, and weight loss. Congenital adrenal hyperplasia, a genetic ailment causing...

